ABCG2 and renal carcinoma: In the current study, we demonstrated that the inhibition of NRF2 expression in ovarian and renal carcinoma cells led to the suppression of c-MET/EGFR levels through miR-206 upregulation, and the NRF2-silencing-induced miR-206 could reduce BCRP expression, resulting in chemosensitization to anticancer drug treatment.